[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biodexa Pharmaceuticals Plc ADR (BDRX)

Biodexa Pharmaceuticals Plc ADR (BDRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,353
  • Shares Outstanding, K 1,996
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,420 K
  • EBIT $ 0 M
  • EBITDA $ -11 M
  • 60-Month Beta 1.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.02

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6500 +1.25%
on 07/23/26
3.1400 -46.79%
on 07/01/26
-0.9393 (-35.99%)
since 06/24/26
3-Month
1.6500 +1.25%
on 07/23/26
5.0800 -67.11%
on 05/07/26
-1.6294 (-49.37%)
since 04/24/26
52-Week
1.6500 +1.25%
on 07/23/26
59.4000 -97.19%
on 10/09/25
-42.5843 (-96.22%)
since 07/24/25

Most Recent Stories

More News
With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

CARDIFF, UNITED KINGDOM / ACCESS Newswire / March 19, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the...

BDRX : 1.6701 (-0.59%)
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment...

BDRX : 1.6701 (-0.59%)
Biodexa Stock Surges On FDA's Fast-Track Tag For Treatment Of Cancer-Causing Condition: Retail Confidence Peaks

The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer.

BDRX : 1.6701 (-0.59%)
Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical...

BDRX : 1.6701 (-0.59%)
Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year’s End

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:CRDF),(NASDAQ:BDRX),(NASDAQ:DRUG),(NYSE:LLY) EQNX::TICKER_END

DRUG : 72.83 (+2.16%)
BDRX : 1.6701 (-0.59%)
LLY : 1,200.51 (+1.23%)
PTN : 8.17 (+1.69%)
CRDF : 0.8157 (-2.67%)
Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year's End

/PRNewswire/ -- About 9.4% of the world population is aged 65 or above. Older people typically consume more medicines than the people in other age group...

DRUG : 72.83 (+2.16%)
BDRX : 1.6701 (-0.59%)
LLY : 1,200.51 (+1.23%)
PTN : 8.17 (+1.69%)
CRDF : 0.8157 (-2.67%)

Business Summary

BIODEXA PHARMA is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3(TM) platform for delivering therapeutics across the blood-brain barrier and the treatment of central nervous system...

See More

Key Turning Points

3rd Resistance Point 2.0533
2nd Resistance Point 1.9667
1st Resistance Point 1.8233
Last Price 1.6701
1st Support Level 1.5933
2nd Support Level 1.5067
3rd Support Level 1.3633

See More

52-Week High 59.4000
Fibonacci 61.8% 37.3395
Fibonacci 50% 30.5250
Fibonacci 38.2% 23.7105
Last Price 1.6701
52-Week Low 1.6500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.